Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 18/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3085480 | 0.83 | PTGS2 (0.44) | PTGS2TGFBR1 | |
| SCHEMBL4866980 | 0.81 | TGFBR1 (0.44) | PTGS2TGFBR1MAPK14 | |
| SCHEMBL3091507 | 0.79 | PTGS2 (0.42) | PTGS2TGFBR1MAPK14KDR | |
| SCHEMBL4859618 | 0.78 | TGFBR1 (0.57) | TGFBR1MAPK14 | |
| SCHEMBL4857759 | 0.64 | PTGS2 (0.44) | PTGS2TGFBR1MAPK14KDR | |
| SCHEMBL4868431 | 0.62 | TGFBR1 (0.57) | PTGS2TGFBR1MAPK14 | |
| SCHEMBL3092632 | 0.62 | PTGS2 (0.42) | PTGS2TGFBR1MAPK14KDR | |
| SCHEMBL4860133 | 0.60 | TGFBR1 (0.44) | TGFBR1MAPK14 | |
| SCHEMBL4860144 | 0.60 | TGFBR1 (0.43) | PTGS2TGFBR1MAPK14 | |
| SCHEMBL7836982 | 0.59 | PTGS2 (1.00) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790741-B2 | Imidazothiazoles and imidazoxazoles | ABBOTT LABORATORIES (US) | 2010-09-07 | — | — | US | claimed |
| EP-2068869-A2 | NOVEL IMIDAZOTHIAZOLES AND IMIDAZOXAZOLES | Abbott Laboratories (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080161341-A1 | Novel imidazothiazoles and imidazoxazoles | ABBVIE INC. | 2008-07-03 | — | — | US | claimed |
| WO-2008063287-A2 | NOVEL IMIDAZOTHIAZOLES AND IMIDAZOXAZOLES | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | WO | claimed |
| US-7790741-B2 | Imidazothiazoles and imidazoxazoles | ABBOTT LABORATORIES (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2068869-A2 | NOVEL IMIDAZOTHIAZOLES AND IMIDAZOXAZOLES | Abbott Laboratories (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080161341-A1 | Novel imidazothiazoles and imidazoxazoles | ABBVIE INC. | 2008-07-03 | — | — | US | disclosed |
| WO-2008063287-A2 | NOVEL IMIDAZOTHIAZOLES AND IMIDAZOXAZOLES | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161341-A1 | Novel imidazothiazoles and imidazoxazoles | MAP3K1, MAP3K19, MAP3K5 | PTGS2 805/4885TGFBR1 1209/4885MAPK14 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.